Extension Notice and Research Funding Adjustment under Sub-License and Collaboration Agreement between MedImmune LLC and Humabs BioMed SA
This letter from Humabs BioMed SA to MedImmune LLC confirms that Humabs agrees to expand the scope of their existing Sub-License and Collaboration Agreement to include research on Klebsiella, as allowed by the contract. Humabs also requests an increase in research funding payments due to higher research costs. The letter serves as formal notification of these changes and expresses Humabs' intent to continue the collaboration.
Exhibit 10.36
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
David A. Vallo
Senior Protect Manager
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878
USA
Bellinzona, April 19, 2013
Re: Sub-License and Collaboration Agreement dated as of March 20, 2012 (“Agreement”) between MedImmune LLC (“MedImmune”) and Humabs BioMed SA (“Humabs”)
Dear Mr. Vallo,
We hereby notify MedImmune of Humabs’ agreement to extend the scope of the Research Project to work on Klebsiella, which has been elected as the Extra Target in accordance with Section 5.19.2 of the Agreement.
In consideration of the generally increased research costs per FTE at Humabs, we submits to MedImmune the request to increase the amount of Research Funding payments (Section 5.23.1.1. of the Agreement) from [***] of the Research Term.
Thank you for your time and cooperation. We also continue to look forward to a successful collaboration with MedImmune.
Yours sincerely,
/s/ Alcide Barberis
Alcide Barberis, PhD
President and CEO
Humabs BioMed SA
Via Mirasole 1
CH-6500 Bellinzona, Switzerland
[***]
